Immunotherapy for neuroblastoma Book Section

  


Authors: Kudva, A.; Modak, S.
Editor: Ray, S. K.
Article/Chapter Title: Immunotherapy for neuroblastoma
Abstract: Current therapeutic approaches for high-risk neuroblastoma include dose-intensive chemotherapy, surgical and radiotherapeutic interventions that are associated with long- and short-term toxicities. Immunotherapy utilizes mechanisms of action that are not cross-reactive with other antitumor modalities and reduce exposure to cytotoxic agents, improving both the survival and quality of life in patients treated for high-risk neuroblastoma. In this chapter, we review antineuroblastoma immunotherapy strategies in clinical use and preclinical development. These include monoclonal antibodies and cytokines, immunoconjugates, chemoimmunotherapy, radioimmunotherapy, adoptive cell therapies, and cancer vaccines. © 2019 Elsevier Inc. All rights reserved.
Keywords: monoclonal antibodies; immunotherapy; cancer vaccines; neuroblastoma; radioimmunotherapy; adoptive immunotherapy; gd2; chemoimmunotherapy
Book Title: Neuroblastoma: Molecular Mechanisms and Therapeutic Interventions
ISBN: 978-0-12-812005-7
Publisher: Elsevier Inc.  
Publication Place: London, United Kingdom
Date Published: 2019-01-01
Start Page: 147
End Page: 173
Language: English
DOI: 10.1016/b978-0-12-812005-7.00009-6
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081394510&doi=10.1016%2fB978-0-12-812005-7.00009-6&partnerID=40&md5=1130e6d4ba007105487df3f46c5f5894
Notes: Book Chapter: 9 -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Shakeel Modak
    249 Modak
  2. Anupa Kudva
    3 Kudva
Related MSK Work